TCIM
SNDX icon

TIAA CREF Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

TIAA CREF Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$528K Buy
100,555
+32,043
+47% +$183K ﹤0.01% 2578
2018
Q4 		$305K Buy
68,512
+35,200
+106% +$193K ﹤0.01% 2767
2018
Q3 		$269K Buy
33,312
+3,503
+12% +$25K ﹤0.01% 2913
2018
Q2 		$209K Sell
29,809
-68,230
-70% -$669K ﹤0.01% 3028
2018
Q1 		$1.4M Buy
98,039
+44,655
+84% +$474K ﹤0.01% 2280
2017
Q4 		$468K Buy
53,384
+3,304
+7% +$32.7K ﹤0.01% 2802
2017
Q3 		$586K Buy
50,080
+596
+1% +$7.31K ﹤0.01% 2766
2017
Q2 		$691K Buy
49,484
+26,560
+116% +$304K ﹤0.01% 2716
2017
Q1 		$315K Buy
22,924
+6,091
+36% +$63.3K ﹤0.01% 2915
2016
Q4 		$121K Buy
16,833
+6,073
+56% +$66.6K ﹤0.01% 3077
2016
Q3 		$163K Sell
10,760
-539
-5% -$7.09K ﹤0.01% 3066
2016
Q2 		$111K Buy
+11,299
New +$155K ﹤0.01% 3129

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TIAA CREF Investment Management's SNDX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Syndax Pharmaceuticals (SNDX) stake by 47% in Q1 2019, buying an estimated $183K and bringing the position to 100,555 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #2578.

TIAA CREF Investment Management first reported a position in SNDX in Q2 2016 and has held it in 12 quarters since. The position peaked at $1.4M in Q1 2018. 69 funds tracked by Wall St. Rank hold SNDX as of Q1 2019.

  • TIAA CREF Investment Management held 100,555 shares of Syndax Pharmaceuticals worth $528K as of Q1 2019.
  • TIAA CREF Investment Management bought 32,043 Syndax Pharmaceuticals shares in Q1 2019, an estimated $183K.
  • Syndax Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2578 holding.
  • TIAA CREF Investment Management first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 12 quarters since.
  • TIAA CREF Investment Management's Syndax Pharmaceuticals position peaked at $1.4M in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.